Stefan Hans Hohnloser

Q: What Schools Are Affiliated With Stefan Hans Hohnloser

Stefan Hans Hohnloser is affiliated with the following schools: Goethe University Frankfurt, Aarhus University, Uppsala University, University of Freiburg, University of Pavia, McMaster University

Stefan Hans Hohnloser's AcademicInfluence.com Rankings

Philosophy

#4079

World Rank

#6462

Historical Rank

Logic

#1620

World Rank

#2421

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Stefan Hans Hohnloser Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stefan Hans Hohnloser's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Apixaban versus warfarin in patients with atrial fibrillation. (2011) (6217)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016) (4929)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012) (3704)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. (2012) (3356)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016) (2451)
Apixaban in patients with atrial fibrillation. (2011) (1889)
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial (2006) (1889)
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. (2009) (1867)
Cardiac-resynchronization therapy for mild-to-moderate heart failure. (2010) (1559)
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. (2004) (1434)
Rhythm control versus rate control for atrial fibrillation and heart failure. (2008) (1406)
Subclinical atrial fibrillation and the risk of stroke. (2012) (1391)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial (2011) (1141)
Effect of dronedarone on cardiovascular events in atrial fibrillation. (2009) (1047)
Guidelines on management (diagnosis and treatment) of syncope. (2001) (1002)
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (2017) (949)
Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial (2000) (866)
Guidelines on management (diagnosis and treatment) of syncope--update 2004. (2004) (838)
Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias: Implications for Clinical Trials (2001) (683)
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. (2006) (666)
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. (2007) (611)
Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes (2002) (562)
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2012) (531)
Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events (2014) (523)
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. (2009) (499)
Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. (2004) (484)
[Guidelines on management (diagnosis and treatment) of syncope. Update 2004. Executive summary]. (2004) (482)
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. (2007) (462)
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. (2005) (443)
Outcome parameters for trials in atrial fibrillation: executive summary. (2007) (413)
Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. (1999) (403)
Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. (1998) (378)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial (2012) (375)
Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology. (2011) (374)
Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia (1994) (374)
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT (2017) (373)
Dronedarone in high-risk permanent atrial fibrillation. (2011) (368)
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy (2012) (367)
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. (2014) (365)
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation (2015) (362)
Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study. (1998) (356)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis (2013) (346)
Risk stratification for sudden cardiac death: current status and challenges for the future† (2014) (336)
American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardi (2008) (321)
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. (2006) (320)
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. (2003) (315)
Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomised trial (2001) (292)
More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. (1995) (285)
Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties (2003) (278)
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. (2015) (276)
Interpretation and Classification of Microvolt T Wave Alternans Tests (2002) (270)
Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. (1994) (270)
Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. (2007) (269)
The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. (2009) (265)
Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. (1994) (263)
Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?: Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry (2010) (262)
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). (2014) (252)
Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (2009) (250)
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. (2011) (246)
Analysis of 12-Lead T-Wave Morphology for Risk Stratification After Myocardial Infarction (2000) (246)
Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. (2009) (238)
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) (2008) (235)
Rationale and design of the Apixaban for the Reduction of Thrombo‐Embolism in Patients With Device‐Detected Sub‐Clinical Atrial Fibrillation (ARTESiA) trial (2017) (224)
T Wave Alternans as a Predictor of Recurrent Ventricular Tachyarrhythmias in ICD Recipients: Prospective Comparison with Conventional Risk Markers (1998) (223)
Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE) (2015) (222)
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study (2013) (222)
Irbesartan in patients with atrial fibrillation. (2011) (215)
Digoxin-associated mortality: a systematic review and meta-analysis of the literature. (2015) (215)
Risk for Permanent Pacemaker After Transcatheter Aortic Valve Implantation: A Comprehensive Analysis of the Literature (2012) (209)
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation (2017) (207)
Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. (1988) (204)
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). (2013) (196)
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial (2012) (195)
Atrial Fibrillation and Congestive Heart Failure: Specific Considerations at the Intersection of Two Common and Important Cardiac Disease Sets (2002) (194)
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. (2015) (190)
Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. (2003) (190)
Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. (1991) (188)
Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. (1995) (185)
American Heart Association/american College of Cardiology Foundation/heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardi (2008) (181)
Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. (2003) (177)
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial (2012) (176)
T Wave Alternans During Exercise and Atrial Pacing in Humans (1997) (174)
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. (2010) (173)
Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Trial (2006) (169)
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. (2006) (165)
Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications (1995) (161)
Pace‐Termination and Pacing for Prevention of Atrial Tachyarrhythmias: Results from a Multicenter Study with an Implantable Device for Atrial Therapy (2001) (157)
Analysis of Creatine Kinase, CK‐MB, Myoglobin, and Troponin T Time‐Activit Curves for Early Assessment of Coronary Artery Reperfusion After Intravenous Thrombolysis (1993) (155)
Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. (1994) (153)
Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction: Insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT) (2010) (148)
Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT) (2012) (146)
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. (1997) (141)
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. (2016) (136)
Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. (1994) (135)
Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter Defibrillator (2004) (135)
Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary. (2005) (134)
Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable (2011) (133)
Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. (2010) (131)
Digoxin and Mortality in Patients With Atrial Fibrillation. (2018) (131)
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials (2018) (130)
Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. (1996) (129)
Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. (2012) (128)
New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation (2008) (126)
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) (2013) (123)
Association Between Atrial Fibrillation and Appropriate Implantable Cardioverter Defibrillator Therapy:Results from a Prospective Study (2000) (122)
Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. (2001) (121)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. (2016) (119)
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. (2006) (115)
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. (2014) (114)
Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. (1999) (114)
Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. (1992) (110)
Drug therapy : Sotalol (1994) (109)
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial (2019) (109)
‘2012 focused update of the ESC Guidelines for the management of atrial fibrillation’ [Eur Heart J (2012); 33(21):2719–2747] (2013) (103)
The 1+1 Trial: A Prospective Trial of a Dual- Versus a Single-Chamber Implantable Defibrillator in Patients With Slow Ventricular Tachycardias (2004) (101)
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. (2014) (101)
Electrophysiologic Features of Torsades de Pointes: (1997) (96)
Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. (2013) (96)
Mechanisms of Sudden Cardiac Death in Myocardial Infarction Survivors: Insights From the Randomized Trials of Implantable Cardioverter-Defibrillators (2007) (92)
Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter–Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS (Substrate Modification Study) (2017) (91)
ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). (2012) (90)
Prevalence of Circadian Variations and Spontaneous Variabilit of Cardiac Disorders and ECG Changes Suggestive of Myocardial Ischemia in Systemic Arterial Hypertension (1992) (90)
Evidence regarding clinical use of microvolt T-wave alternans. (2008) (90)
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2014) (89)
Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. (2015) (88)
Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device. (2001) (87)
Quantitative Assessment of Microvolt T‐Wave Alternans in Patients with Congestive Heart Failure (2005) (86)
Insulation Defects of Thin High‐Voltage ICD Leads: (2011) (86)
Spontaneous variability and circadian distribution of ectopic activity in patients with malignant ventricular arrhythmia. (1988) (85)
Rationale and Design of ATHENA: A Placebo‐Controlled, Double‐Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter (2007) (84)
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. (2016) (83)
Heart Rate Variability Used as an Arrhythmia Risk Stratifier After Myocardial Infarction (1997) (82)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. (2016) (81)
Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. (2003) (80)
Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. (2004) (80)
Atrial-selective approaches for the treatment of atrial fibrillation. (2008) (78)
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. (2012) (75)
Safety and efficacy of advanced atrial pacing therapies for atrial tachyarrhythmias in patients with a new implantable dual chamber cardioverter-defibrillator. (2002) (74)
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. (2010) (74)
Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. (2018) (73)
External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application. (2007) (72)
Intraindividual Reproducibility of Heart Rate Variability (1992) (72)
Dronedarone: An Emerging Agent with Rhythm‐ and Rate‐Controlling Effects (2006) (71)
Patency of infarct-related artery. Effect of restoration of anterograde flow on vagal reflexes. ATRAMI (Automatic Tone and Reflexes After Myocardial Infarction) Investigators. (1996) (70)
Task force on syncope, European Society of Cardiology. Part 2. Diagnostic tests and treatment: summary of recommendations. (2001) (68)
Task force on syncope, European Society of Cardiology. Part 1. The initial evaluation of patients with syncope. (2001) (66)
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. (2014) (66)
Risk of development of delayed atrioventricular block after slow pathway modification in patients with atrioventricular nodal reentrant tachycardia and a pre-existing prolonged PR interval. (2001) (64)
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial (2019) (64)
Dronedarone in patients with congestive heart failure: insights from ATHENA (2010) (63)
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). (2011) (62)
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. (2012) (61)
Interaction Between Digoxin and Dronedarone in the PALLAS Trial (2014) (61)
Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation (2018) (61)
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. (2019) (59)
Implantable cardioverter-defibrillator lead disintegration at the level of the tricuspid valve. (2008) (59)
The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol. (2000) (59)
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction (2005) (59)
Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death. (2012) (59)
Complications leading to surgical revision in implantable cardioverter defibrillator patients: comparison of patients with single-chamber, dual-chamber, and biventricular devices. (2009) (58)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease (2020) (57)
Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias. (1987) (57)
Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design (2009) (56)
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study (2017) (55)
Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death: The ALPHEE Study (2011) (55)
Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices (2013) (53)
Incidence of Cardiac Perforation With Conventional and With Leadless Pacemaker Systems: A Systematic Review and Meta‐Analysis (2017) (52)
Changes in Plasma Epinephrine Concentration and in Heart Rate During Head‐Up Tilt Testing in Patients with Neurocardiogenic Syncope: (1996) (51)
Corrigendum to: ‘2012 focused update of the ESC Guidelines for the management of atrial fibrillation’ [Eur Heart J (2012); 33(21):2719–2747] (2013) (51)
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. (2007) (50)
Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. (2012) (49)
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy (2014) (48)
Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. (2016) (48)
Differential Effects of D‐Sotalol, Quinidine, and Amiodarone on Dispersion of Ventricular Repolarization in the Isolated Rabbit Heart (1997) (48)
Atrial Pacing in the Prevention of Paroxysmal Atrial Fibrillation: First Results of a New Combined Algorithm (2000) (47)
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study (2019) (45)
Bundle Branch Reentrant Tachycardia in Patients with Apparent Normal His‐Purkinje Conduction: The Role of Functional Conduction Impairment (2002) (45)
Intracardiac QRS Electrogram Width—An Arrhythmia Detection Feature for Implantable Cardioverter Defibrillators: Exercise Induced Variation as a Base for Device Programming (1998) (45)
Upgrading to biventricular pacing/defibrillation systems in right ventricular paced congestive heart failure patients: prospective assessment of procedural parameters and response rate. (2007) (45)
Risk Stratification Using T‐Wave Alternans: More Questions Waiting to be Answered (2008) (44)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. (2016) (44)
Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) (2006) (43)
Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). (2001) (43)
Efficacy and Safety of ICD Therapy in a Population of Elderly Patients Treated with Optimal Background Medication (2005) (43)
Prospective randomized comparison of durability of bidirectional conduction block in the cavotricuspid isthmus in patients after ablation of common atrial flutter using cryothermy and radiofrequency energy: the CRYOTIP study. (2009) (43)
Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report (2016) (42)
Effect of hypokalemia on susceptibility to ventricular fibrillation in the normal and ischemic canine heart. (1986) (42)
Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure (2015) (42)
Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation (2011) (42)
Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. (2019) (42)
Usefulness of esmolol in unstable angina pectoris (1991) (41)
Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation? (2005) (40)
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study (2011) (40)
A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group. (1996) (40)
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation (2019) (39)
Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. (2022) (39)
Atrial Fibrillation: Maintaining Stability of Sinus Rbythm or Ventricular Rate Control? The Need for Prospective Data: The PIAF Trial (1997) (39)
Catheter ablation guided by termination of postinfarction ventricular tachycardia by pacing with nonglobal capture. (2004) (37)
Incidence of Atrial Tachyarrhythmias in Pacemaker Patients: Results from the Balanced Evaluation of Atrial Tachyarrhythmias in Stimulated Patients (BEATS) Study (2006) (37)
Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias. (1986) (36)
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial (2015) (36)
Arrhythmic death in implantable cardioverter defibrillator patients: a long-term study over a 10 year implantation period. (2009) (35)
Changes in Autonomic Tone Following Thrombolytic Therapy for Acute Myocardial Infarction: (1994) (35)
Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. (1989) (35)
Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction. (2009) (35)
Discrimination Between Ventricular and Supraventricular Tachycardia by Dual Chamber Cardioverter Defibrillators: Importance of the Atrial Sensing Function (2001) (34)
Basic Autonomic Tests (1998) (34)
EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. (2019) (34)
Heart Failure Complicated by Atrial Fibrillation: Mechanistic, Prognostic, and Therapeutic Implications (2003) (34)
Relevance of Electrical Remodeling in Human Atrial Fibrillation: Results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial Mechanisms of Atrial Fibrillation Study (2012) (33)
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial (2013) (33)
Current evidence base for use of the implantable cardioverter-defibrillator. (2013) (33)
Combined Antiplatelet Therapy in Atrial Fibrillation: (2003) (33)
Analysis During Sinus Rhythm of Critical Sites in Reentry Circuits of Postinfarction Ventricular Tachycardia (2002) (33)
Morphology Discrimination: A Beat‐to‐Beat Algorithm for the Discrimination of Ventricular from Supraventricular Tachycardia by Implantable Cardioverter Defibrillators (2001) (32)
The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients (2017) (32)
The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: a randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. (2012) (31)
Heart rate turbulence and other autonomic risk markers for arrhythmia risk stratification in dilated cardiomyopathy. (2008) (31)
[QT-dispersion in the surface ECG as a parameter of increased electrical vulnerability in acute myocardial ischemia]. (1993) (31)
Ablation of Atypical Atrial Flutter Guided by the Use of Concealed Entrainment in Patients Without Prior Cardiac Surgery (2000) (30)
[Reproducibility of heart rate variability measurements in repeated 24-hour long-term ECG registration]. (1993) (30)
Cephalic vs. subclavian lead implantation in cardiac implantable electronic devices: a systematic review and meta-analysis (2018) (30)
Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. (2020) (29)
Changing late prognosis of acute myocardial infarction: impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. (2003) (29)
Bedside risk stratification after acute myocardial infarction: prospective evaluation of the use of heart rate and left ventricular function. (2005) (29)
Silent myocardial ischemia as a predisposing factor for ventricular fibrillation. (1988) (29)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) (2014) (28)
Catheter Ablation of Frequently Recurring Ventricular Fibrillation in a Patient after Aortic Valve Repair (2004) (28)
Prevalence of a Shared Isthmus in Postinfarction Patients with Pleiomorphic, Hemodynamically Tolerated Ventricular Tachycardias (2002) (28)
Thromboembolic Risk of Patients Referred for Radiofrequency Catheter Ablation of Typical Atrial Flutter Without Prior Appropriate Anticoagulation Therapy (2003) (28)
Ventricular Rate Stabilization for the Prevention of Pause Dependent Ventricular Tachyarrhythmias: Results from a Prospective Study in 309 ICD Recipients (2002) (28)
The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review. (2022) (27)
How to analyze T-wave alternans. (2005) (27)
Heart Rate Variability to Assess Changes in Cardiac Vagal Modulation Prior to the Onset of Paroxysmal Atrial Fibrillation in Patients With and Without Structural Heart Disease (1999) (27)
Prevention of Immediate Reinitiation of Atrial Tachyarrhythmias by High‐Rate Overdrive Pacing: (2003) (27)
QT dispersion in exercise-induced myocardial hypertrophy. (1999) (27)
Amiodarone and dronedarone: An update. (2016) (27)
Novel anti-arrhythmic drugs for atrial fibrillation management. (2007) (26)
Circadian Variation of Heart Rate Variability in Postinfarction Patients With and Without Life‐Threatening Ventricular Tachyarrhythmias (1995) (26)
Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis (2016) (26)
First worldwide clinical experience with a new dual chamber implantable cardioverter defibrillator. Advantages and complications. The Ventak AV II DR investigators. (1999) (26)
Coronary Sinus Side Branches for Cardiac Resynchronization Therapy: Prospective Evaluation of Availability, Implant Success, and Procedural Determinants (2008) (26)
Torsade de pointes complicating drug treatment of low‐malignant forms of arrhythmia: Four case reports (1994) (26)
T-wave alternans negative coronary patients with low ejection fraction and benefit from defibrillator implantation☆ (2003) (25)
Torsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditis (2001) (25)
Macroscopic T Wave Alternans as a Harbinger of Sudden Death (1999) (25)
Why Did Mode Switching Occur? (2000) (24)
Worldwide Clinical Experience with aDown‐Sized Active Can ImplantableCardioverier Defibrillator in 162 ConsecutivePatients (1998) (24)
Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy Results of a Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study (1995) (24)
Insights Into the Pathogenesis of Sudden Cardiac Death From Analysis of Circadian Fluctuations of Potential Triggering Factors (1994) (24)
Amiodarone-associated macroscopic T-wave alternans and torsade de pointes unmasking the inherited long QT syndrome. (2007) (24)
Quality of life in atrial fibrillation: an increasingly important issue (2003) (24)
Atrial fibrillation--maintaining sinus rhythm versus ventricular rate control: the PIAF trial. Pharmacological Intervention in Atrial Fibrillation. (1998) (24)
Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial (2016) (23)
Q‐T prolongation and torsades de pointes in a patient with subarachnoid hemorrhage (1984) (23)
A randomized trial of budiodarone in paroxysmal atrial fibrillation (2012) (23)
Prospective Evaluation of a Two‐Step Therapeutic Strategy in Neurocardiogenic Syncope: Midodrine as Second Line Treatment in Patients Refractory to β‐Blockers (1999) (23)
The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. (2013) (22)
MICRA Leadless Pacemaker on Autopsy. (2016) (22)
Sustained Monomorphic Ventricular Tachycardia Ablation from the Aortic Sinus of Valsalva (2002) (22)
Location of the Lower Turnaround Point in Typical AV Nodal Reentrant Tachycardia: (2000) (22)
Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma. (2011) (22)
Flecainide‐induced aggravation of ventricular tachycardia (1983) (21)
Microvolt T-Wave Alternans (2011) (21)
Effects of Upgrade Versus De Novo Cardiac Resynchronization Therapy on Clinical Response and Long-Term Survival: Results from a Multicenter Study (2017) (21)
Adenosine‐induced Atrial Fibrillation (2000) (21)
Septal Q waves in surface electrocardiographic lead V6 exclude minimal ventricular preexcitation. (1999) (21)
Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. (2019) (21)
Efficacy and safety of sotalol in patients with complex ventricular arrhythmias. (1992) (20)
Radiofrequency Catheter Ablation of Atrial Flutter After Orthotopic Heart Transplantation (1996) (20)
Characterization of Human Cardiac Kv1.5 Inhibition by the Novel Atrial-selective Antiarrhythmic Compound AVE1231 (2008) (20)
Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. (2008) (20)
Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database (2019) (19)
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. (2016) (19)
Robotically Enhanced Placement of Left Ventricular Epicardial Electrodes During Implantation of a Biventricular Implantable Cardioverter Defibrillator System (2002) (19)
Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation (2014) (19)
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial (2020) (19)
Pacing to Prevent Atrial Fibrillation (2003) (19)
Biventricular pacing does not affect microvolt T-wave alternans in heart failure patients. (2008) (18)
Influence of beta 2-adrenoceptor stimulation and blockade on cardiac electrophysiologic properties and serum potassium concentration in the anesthetized dog. (1987) (18)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. (2017) (18)
Drug treatment of atrial fibrillation: what have we learned? (1997) (17)
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. (2020) (17)
Effect of coronary ischemia on QT dispersion. (2000) (17)
QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards (1991) (17)
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial (2017) (17)
Indications and Limitations of Class II and III Antiarrhythmic Drugs in Atrial Fibrillation (1994) (17)
Stroke prevention in atrial fibrillation: do we still need warfarin? (2012) (17)
A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation (2018) (16)
Relation of diurnal variation of ventricular repolarization to ventricular ectopic activity and modification by sotalol. (1993) (16)
Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. (2019) (16)
Effects of adrenergic and muscarinic receptor stimulation on serum potassium concentrations and myocardial electrical stability. (1986) (16)
Discrete Systolic Potentials During Ventricular Tachycardia in Patients with Prior Myocardial Infarction (1999) (16)
T wave alternans and left ventricular ejection fraction, but not QT variability index, predict appropriate ICD discharge. (1999) (16)
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. (2007) (16)
Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase. (1990) (16)
Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. (2021) (16)
Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies (2011) (16)
Assessment of Microvolt T‐Wave Alternans in High‐Risk Patients with the Congenital Long‐QT Syndrome (2009) (16)
T-wave alternans: a pathophysiological link to human ventricular tachyarrhythmias. (2008) (16)
Sudden cardiac death recorded during ambulatory electrocardiographic monitoring (1984) (15)
What do implantable cardioverter/defibrillators teach us about the mechanisms of sudden cardiac death? (2001) (15)
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. (2003) (15)
Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. (2016) (15)
Clinical value of T-wave alternans assessment. (2002) (15)
A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone. (2011) (15)
Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. (2011) (15)
Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial (2013) (15)
Rhythm or Rate Control in Atrial Fibrillation: Insights from the Randomized Controlled Trials (2003) (15)
[Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects]. (1994) (14)
Radiofrequency catheter ablation in patients with symptomatic atrial flutter/tachycardia after orthotopic heart transplantation (2006) (14)
Usefulness of the WCD in patients with suspected tachymyopathy (2017) (14)
Effects of digitalis on mortality in a large cohort of implantable cardioverter defibrillator recipients: results of a long-term follow-up study in 1020 patients. (2016) (14)
Identification of patients after myocardial infarction at risk of life-threatening arrhythmias (1999) (14)
American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death (2008) (14)
Microvolt T-wave alternans testing has a role in arrhythmia risk stratification. (2012) (14)
Properties of a Time-Dependent Potassium Current in Pig Atrium: Evidence for a Role of Kv1.5 in Repolarization (2006) (14)
Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase. (1988) (14)
Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). (2001) (14)
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention (2020) (13)
Prediction of efficacy and tolerance of oral mexiletine by intravenous lidocaine application (1988) (13)
“Twiddler Syndrome” in a Subpectorally Implanted Cardioverter Defibrillator (2002) (13)
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. (2020) (13)
Guidelines for Implantation of Automatic Cardioverter/Defibrillators (2000) (13)
Suppression of Atrial Tachyarrhythmias by Pacing (2002) (13)
Permanent Pacing Is a Risk Factor for the Development of Heart Failure (2005) (13)
Ventricular Arrhythmias: Antiadrenergic Therapy for the Patient with Coronary Artery Disease (2005) (13)
Usefulness of ckmb and troponin t determinations in patients with acute myocardial infarction complicated by ventricular fibrillation (1993) (12)
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. (2019) (12)
Abstract 4097: Rhythm- and Rate-Controlling Effects of Dronedarone in Patients with Atrial Fibrillation: Insights From the ATHENA Trial (2008) (12)
β‐Blocker Therapy in Atrial Fibrillation (2003) (12)
A combined anatomic and electrophysiologic substrate based approach for sudden cardiac death risk stratification. (2013) (11)
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? (2010) (11)
Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group. (1991) (11)
Mechanism of Ventricular Tachycardia Termination by Pacing at Left Ventricular Sites in Patients with Coronary Artery Disease (2002) (11)
An Unusual Cause of ICD Shock (1997) (11)
The Relationship Between Atrial High-Rate Episodes and Stroke: The Asymptomatic Stroke and Atrial Fibrillation Evaluation in Pacemaker Patients (ASSERT) Trial (2010) (11)
Implantable Cardioverter Defibrillator Therapy in a Patient with the Idiopathic Long QT Syndrome (1996) (11)
2016 ESC guidelines for the diagnosis and treatment of atrial fibrillation developed in collaboration with the EACTS (2017) (11)
Usefulness of Risk Stratification for Future Cardiac Events in Infarct Survivors with Severely Depressed Versus Near‐Normal Left Ventricular Function: Results From a Prospective Long‐Term Follow‐Up Study (2003) (11)
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial (2019) (11)
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. (2019) (11)
ST segment analysis for assessment of coronary artery patency: comparison of surface ECG and Holter recordings. (1992) (10)
An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. (2014) (10)
The hazards of interrupting anticoagulation therapy in atrial fibrillation. (2012) (10)
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE‐AF study. (2018) (10)
Worldwide clinical experience with a down-sized active can implantable cardioverter defibrillator in 162 consecutive patients. Worldwide 7221 ICD Investigators. (1998) (10)
Prediction of early recurrence of atrial fibrillation after external cardioversion by means of P wave signal-averaged electrocardiogram (2003) (10)
Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group. (1990) (10)
Erratum to: Relationship between clinical and echocardiography-derived parameters and atrial activation as measured by the P-wave signal-averaged electrocardiogram (2002) (10)
[Intra-individual reproducibility of tilt table studies in diagnosis of vasovagal syncope]. (1993) (10)
Uninterrupted anticoagulation with non‐vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials (2018) (9)
Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter (2012) (9)
Safety and efficacy of a dual chamber implantable cardioverter defibrillator capable of slow ventricular tachycardia discrimination: a randomized study. (2003) (9)
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUA (2019) (9)
Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. (1992) (9)
Milestones in the management of atrial fibrillation. (2009) (9)
Amiodarone Therapy After Previous Sotalol-induced Torsade de Pointes: Analysis of QT Dispersion to Predict Proarrhythmia (1996) (9)
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): rationale, design and specific aims. (2003) (9)
[P-wave signal averaging-ECG: normal values and reproducibility]. (2001) (9)
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE‐LY trial analysis (2018) (9)
APIXABAN IS EFFICACIOUS AND SAFE IN PATIENTS WITH ATRIAL FIBRILLATION USING CONCOMITANT AMIODARONE: AN ANALYSIS FROM THE ARISTOTLE TRIAL (2013) (9)
Not All Types of Atrial Fibrillation Carry the Same Stroke Risk, but Most Benefit From Oral Anticoagulation. (2017) (9)
Atrial flutter in the recipient atrium induced by premature beats arising from the donor atrium 10 years after orthotopic heart transplantation. (1999) (9)
Intracoronary administration of bone marrow-derived mononuclear cells and arrhythmic events in patients with chronic heart failure. (2011) (9)
Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran (2012) (9)
Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. (2017) (9)
[Atrial fibrillation and the autonomic nervous system]. (1994) (9)
Safety and Efficacy of a Dual Chamber Implantable Cardioverter Defibrillator Capable of Slow Ventricular Tachycardia Discrimination: (2003) (9)
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial (2022) (8)
Epicardial CRT-P- and S-ICD Implantation in a Young Patient with Persistent Left Superior Vena Cava (2016) (8)
Prevalence of ventricular arrhythmias during silent myocardial ischemia (1987) (8)
Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation (2013) (8)
Noninvasive evaluation of pulmonary hypertension by quantitative contrast M-mode echocardiography. (1986) (8)
Clinical outcomes after implantation of quadripolar compared to bipolar left ventricular leads in patients undergoing cardiac resynchronization therapy: a systematic review and meta-analysis. (2019) (8)
Dronedarone for prevention of atrial fibrillation: a dose-ranging study (2004) (8)
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. (2019) (8)
Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. (1995) (8)
Cellular properties of C-terminal KCNH2 long QT syndrome mutations: description and divergence from clinical phenotypes. (2008) (8)
Dabigatran and myocardial infarction. (2015) (8)
Beta-blocker therapy in atrial fibrillation. (2003) (8)
The prognostic value of baroreflex sensitivity and heart rate variability after myocardial infarction The ATRAMI study (1996) (8)
Drugs to prevent sudden cardiac death. (2017) (7)
Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation (2010) (7)
Usefulness of Atrial Pacing for Prevention and Termination of Atrial Tachyarrhythmias in a Patient with Persistent Atrial Fibrillation (2002) (7)
Tachycardia after pacemaker implantation in a patient with complete atrioventricular block. (2007) (7)
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. (2014) (7)
Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study (2019) (7)
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. (2019) (7)
Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis (2013) (7)
Antiarrhythmic efficacy and tolerance of oral propafenone in patients with frequent ventricular arrhythmias: experience of a multicentre study. (1989) (7)
Device-Detected Atrial Fibrillation Before and After Hospitalization for Non-cardiac Surgery or Medical Illness: Insights from ASSERT. (2020) (7)
Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation. (1999) (7)
Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Discussion (1992) (7)
Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation : Insights from the ARISTOTLE trial (2015) (7)
Highlights of Heart Rhythm 2004, the Annual Scientific Sessions of the Heart Rhythm Society: May 19 to 22, 2004, in San Francisco, California. (2004) (7)
Severe Intracranial Bleeding Mimicking Acute Inferior Myocardial Infarction with Right Ventricular Involvement (2001) (7)
Drug therapy and microvolt T-wave alternans testing (2003) (7)
New pharmacological options for patients with atrial fibrillation: the ATHENA trial. (2009) (7)
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. (1994) (7)
A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention (2008) (6)
Effects of implantation of quadripolar left ventricular leads on CRT response (2019) (6)
Towards a consensus in rate versus rhythm control for management of atrial fibrillation: insights from the PIAF trial. (2003) (6)
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. (2012) (6)
Effectiveness of single‐ vs dual‐coil implantable defibrillator leads: An observational analysis from the SIMPLE study (2019) (6)
Review : Pharmacological Management of Atrial Fibrillation: An Update (2000) (6)
[Pharmacological cardioversion of atrial fibrillation]. (2005) (6)
Efficacy and Safety of Dronedarone in Patients Previously Treated With Other Antiarrhythmic Agents (2014) (6)
N-Terminal Arginines Modulate Plasma-Membrane Localization of Kv7.1/KCNE1 Channel Complexes (2011) (6)
Immediate Reinitiation of Atrial Tachyarrhythmias after Spontaneous Restoration of Sinus Rhythm in Patients with an Implanted Monitoring Device (2003) (6)
Relative Timing of Isolated Potentials During Postinfarction Ventricular Tachycardia and Sinus Rhythm (2004) (6)
ICD lead type and RV lead position in CRT-D recipients (2018) (6)
Sudden death in dilated cardiomyopathy conventional versus aniodarona treatment (1990) (6)
Relationship between clinical and echocardiography-derived parameters and atrial activation as measured by the P-wave signal-averaged electrocardiogram (2002) (6)
[Induction and increase of cardiac arrhythmia by anti-arrhythmia agents]. (1988) (6)
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study (2020) (6)
The "pill-in-the-pocket" approach to atrial fibrillation. (2005) (6)
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial (2020) (6)
[Local thrombolysis of renal artery embolism]. (1985) (6)
Direct Oral Anticoagulants and Myocardial Infarction: The Dust Is Settling. (2018) (5)
Chapter 91 – T-Wave Alternans (2004) (5)
Stepwise approach to substrate modification of ventricular tachycardia after myocardial infarction. (2006) (5)
Randomized comparison of slow pathway modification within the posteroseptal versus the midseptal area in patients with atrioventricular nodal reentrant tachycardia. (1998) (5)
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study (2019) (5)
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. (2019) (5)
Efficacy and safety of transvenous lead extraction in 108 consecutive patients: a single-centre experience. (2019) (5)
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. (2021) (5)
Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials (2010) (5)
Assessment of acute myocardial necrosis after cardiopulmonary resuscitation and cardioversion by means of combined thallium-201/technetium-99m pyrophosphate tomography (1995) (5)
Exercise‐Induced Symptomatic and Asymptomatic Myocardial Ischemia in Patients with Severe Coronary Artery Disease: Focus on the Efficacy and Safety of Gallopamil (1992) (5)
[Scintigraphy using 111In-labeled antimyosin in Churg-Strauss vasculitis with myocardial involvement]. (1990) (5)
Benefit‐Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation (2012) (5)
Recent primary prevention implantable cardioverter defibrillator trials (2006) (5)
[Drug therapy of supraventricular and ventricular tachyarrhythmias]. (1996) (5)
Reexamination of the Embolic Stroke of Undetermined Source Concept (2021) (5)
Elevated Heart Rate Triggers Action Potential Alternans and Sudden Death. Translational Study of a Homozygous KCNH2 Mutation (2014) (4)
Prevention of recurrent life-threatening arrhythmias: will lipid-lowering therapy make a difference? (2000) (4)
Cardiovascular Disease in the Elderly: Proceedings of the European Society of Cardiology-Cardiovascular Round Table. (2022) (4)
Die neurokardiale Synkope : Pathophysioloige, Diagnostik, Therapie (1995) (4)
Abstract 14808: Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy (2012) (4)
[Neurocardiac syncope: pathophysiology, diagnosis, therapy]. (1995) (4)
[Bepridil--electrophysiologic properties of a new calcium antagonist with an anti-arrhythmia effect]. (1988) (4)
Response to letter regarding article "Temporal relationship between subclinical atrial fibrillation and embolic events". (2015) (4)
Recorded sudden cardiac death: relationship to antiarrhythmic therapy. (1988) (4)
Efficacy and Safety of Transvenous Atrial Cardioversion in Patients with Mitral Valve Disease and Long‐standing Atrial Fibrillation (2000) (4)
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial. (2020) (4)
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. (2021) (4)
Dabigatran for stroke prevention in atrial fibrillation (2012) (4)
Dronedarone: "real-world" data vis-à-vis data from randomized clinical trials. (2014) (4)
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES (2020) (4)
Electrophysiologic Effects of Enoximone in Patients with: Congestive Heart Failure (1989) (4)
[Diprafenone--comparative study of anti-arrhythmia therapy with propafenone]. (1988) (4)
Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia. (1988) (4)
Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial (2019) (4)
Can we predict atrial fibrillation after coronary surgery and why should we? (1998) (3)
Refinement of CARTO-guided substrate modification in patients with ventricular tachycardia after myocardial infarction. (2008) (3)
Influence of Beta2-Adrenoceptor Stimulation and Blockade on Cardiac Electrophysiologic Properties and Serum Potassium Concentration in the Anesthetized Dog (1988) (3)
Combined analysis of three noninvasive harkers for better prediction of reperfusion after thrombolytic therapy for acute myocardial infarction (1991) (3)
β‐Blocking Agents vs. Antiarrhythmic Interventions in Heart Failure Complicated by Arrhythmias (1990) (3)
Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation (2020) (3)
Ventricular Tachycardia and Sudden Cardiac Death (2009) (3)
CRT-D use in heart failure: too little or too much? (2007) (3)
[Brief analysis of heart rate variability in for determining prognosis in the post-myocardial infarct period: methodologically reliable alternative to long-term ECG?]. (1998) (3)
Fighting with the invisible: radiation exposure in cardiac resynchronization therapy. (2009) (3)
[Torsades de pointes and ventricular flutter]. (1984) (3)
Monday, 27 August 2012 (2012) (3)
Defibrillation Testing: The Need for a Definitive Trial (2010) (3)
Anticoagulation in atrial fibrillation (2017) (3)
Pharmacological therapy of atrial fibrillation. (1999) (3)
Subgroup Analysis From the RE-DUAL PCI Trial : Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (2017) (3)
Introduction (2003) (3)
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study (2021) (3)
Distinct Signal Transduction Pathways Govern Physiologic versus Pathologic Cardiac Hypertrophy(The 69th Annual Scientific Meeting of the Japanese Circulation Society) (2005) (3)
Refined risk stratification by heart rate turbulence in patients with reduced left ventricular function early after myocardial infarction: Results of the DINAMIT Holter substudy (2005) (3)
Microvolt T-wave alternans testing provides a reliable means of guiding anti-arrhythmic therapy. (2012) (2)
Pharmacological management of atrial fibrillation: an update. (2000) (2)
Clinical Utility of Baroreflex Sensitivity Measurements (1997) (2)
Automated external defibrillation in emergency medical systems: what has been achieved and where to go? (2006) (2)
DOES RENAL FUNCTION INFLUENCE THE BENEFIT OF DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM RE-DUAL PCI (2018) (2)
Risk Stratification for SCD (2009) (2)
Beat‐to‐Beat Cycle Length Variation During Narrow QRS Complex Tachycardia: What Is the Mechanism? (2005) (2)
Reply: Anticoagulant-Related Nephropathy. (2015) (2)
ICD Therapy in Coronary Artery Disease (2005) (2)
Questionable levels of evidence in new atrial fibrillation guidelines (2013) (2)
Heart Rhythm Society Scientific Program Committee (2007) (2)
[Risk stratification and long-term therapy with amiodarone in patients with idiopathic dilated cardiomyopathy]. (1992) (2)
[Circadian rhythms in coronary heart disease. Their pathophysiology and significance for myocardial ischemia, acute myocardial infarct and sudden cardiac death]. (1992) (2)
[Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation]. (2016) (2)
Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial (2020) (2)
[Therapy with beta receptor blockers in myocardial infarct]. (1994) (2)
[Stratification of patients at risk for sudden cardiac death with special reference to the autonomic nervous system]. (1996) (2)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial (2014) (2)
[Recommendation for the introduction of the International Normalized Ratio as an objective measure for the dosage of oral anticoagulant therapy]. (1994) (2)
P3180The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial (2018) (2)
Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. (2019) (2)
Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation. (2014) (2)
Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter (2021) (2)
Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. (2005) (2)
Arrhythmias AbstractLong-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. Implications for optimal patient care (2004) (2)
[Combined therapy with transvenous cardioverter/defibrillator and anti-bradycardia pacemaker systems]. (1997) (2)
Noninvasive diagnostic methods for cardiac arrhythmias (1997) (2)
IMPACT OF DRONEDARONE STARTED RAPIDLY AFTER AMIODARONE DISCONTINUATION (2010) (1)
Atrial fibrillation control and cardioversion (2001) (1)
IS IT SAFE TO SWITCH OAC IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM A RE-DUAL PCI SUBANALYSIS (2018) (1)
Risk of bleeding with non-vitamin K antagonists and phenprocoumon in routine care patients with non-valvular atrial fibrillation (2016) (1)
‘Patient choice’ concept in AF ESC Guidelines: is the clinician giving up? Reply (2013) (1)
Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. (2014) (1)
69 – T-Wave Alternans (2018) (1)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN ACCORDING TO CHADS2 AND HASBLED RISK SCORES FOR STROKE PREVENTION IN ATRIAL FIBRILLATION (2012) (1)
Paradoxical increase in strokes in the randomized trials on rate versus rhythm control in atrial fibrillation (2003) (1)
Wide QRS Tachycardia with Atrioventricular Dissociation and an HV Interval of 60 msec (1997) (1)
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial. (2021) (1)
911-37 Quinidine or Sotalol-induced Changes in QT-Dispersion During Pharmacological Conversion Therapy of Atrial Fibrillation: Link to Proarrhythmia as Assessed in a Prospective, andomized Trial (1995) (1)
RELATION OF STROKE AND BLEEDING RISK PROFILES TO EFFICACY AND SAFETY OF DABIGATRAN IN ATRIAL FIBRILLATION AFTER PCI: AN ANCILLARY ANALYSIS FROM THE RE-DUAL PCI TRIAL (2018) (1)
Causes of cardioembolic stroke (2018) (1)
T Wave Alternans: What Is the True Practical Clinical Value? (1999) (1)
Noninvasive arrhythmia risk stratification—update 2003 (2003) (1)
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. (2020) (1)
[Drug therapy of ventricular arrhythmias]. (1997) (1)
Comparison of Dabigatran Plus a P2Y12 Inhibitor with Warfarin-Based Triple Therapy across Body Mass Index in RE-DUAL PCI. (2020) (1)
P1-72: Reduction of ventricular pacing in patients with AV block and sinus node disease: Insights from Holter analysis of a new pacing mode (2006) (1)
Amiodarone and Torsade de Pointes (1995) (1)
Recurrent Syncope in a Patient After Myocardial Infarction (2003) (1)
Herz ICD Therapy in Coronary Artery Disease A Reappraisal in 2005 (2005) (1)
[Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference]. (2007) (1)
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". (2013) (1)
P3470Comparative effectiveness and safety of non-vitamin K oral anticoagulants and warfarin in non-valvular atrial fibrillation - a cohort study in 3 Nordic countries (2019) (1)
Syncope on exertion in a young male (2018) (1)
and Clinical UtilityConsensus Guideline by International Society for Holter Microvolt T-Wave Alternans: Physiological Basis, Methods of Measurement, (2011) (1)
Efficacy and tolerance of the new class IB antiarrhythmic barucainide: An intravenous dose‐finding study (1991) (1)
Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? (1998) (1)
[Arrhythmia and anti-arrhythmia therapy as prognostic risks]. (1991) (1)
P3852Treatment initiation patterns among newly diagnosed non-valvular atrial fibrillation patients: Insights from a large German claims database (2018) (1)
[Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine]. (1987) (1)
BLEEDING EVENTS AND THEIR CONSEQUENCES ON CARDIOVASCULAR EVENTS, READMISSION AND NET CLINICAL BENEFIT (2018) (1)
[Clinical profile of the new antiarrhythmic drug dronedarone]. (2010) (1)
Pirmenol versus propafrnon in the treatment of potentially malignant arreytemias (1990) (1)
[T-wave alternans in microwave frequency as a new indicator of disordered ventricular repolarization: pathophysiology, methodology, clinical results]. (1999) (1)
Active-fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights from ASSERT. (2020) (1)
[Effect of sotalol on heart rate variability in patients with symptomatic, complex ventricular arrhythmias]. (1994) (1)
Maintaining Sinus Rhythm Versus Ventricular Rate Control in Atrial Fibrillation: Rationale and Design of the PIAF Trial (2000) (1)
Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin : insights from the ARISTOTLE trial (2016) (1)
STROKE RISK PREDICTION IN PATIENTS WITH ATRIAL FIBRILLATION AND RHEUMATIC HEART DISEASE: RESULTS FROM THE RE-LY AF REGISTRY (2019) (1)
Acute Severe Cardiac Decompensation During Cardiac Resynchronization Therapy: What is the Cause? (2006) (1)
TCT CONNECT-58 Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial (2020) (1)
ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (2004) (1)
The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation (2015) (1)
Electrocardiographic risk stratification in dilative cardiomyopathy: an unfulfilled promise. (2000) (1)
With Atrial Fibrillation (RELY-ABLE) Study The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients (2013) (1)
Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study (2017) (1)
Atrial ﬁbrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications (2009) (1)
Quantitative Analysis of the Duration of Slow Conduction in the Reentrant Circuit of Ventricular Tachycardia After Myocardial Infarction (2008) (1)
P5333Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCI subgroup analysis) (2018) (1)
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. (2023) (1)
Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation an analysis from the SIMPLE study (2018) (0)
Drug therapy and microvolt T-wave alternans testing. Authors' reply (2003) (0)
PHYSICAL EXERCISE IMPROVES MYOCARDIAL REPOLARISATION - A STUDY OF QT-DISPERSION IN TRAINED AND UNTRAINED HEALTHY SUBJECTS 808 (1997) (0)
P3214Implantation of quadripolar left-ventricular leads improves CRT response (2018) (0)
Intravenous lorcainide for symptomatic ventricular tachyarrhythmias: comparison with lidocaine and oral lorcainide. (1988) (0)
Atrial Fibrillation Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and (2012) (0)
P2-32: Correlation between objective and subjective parameters for quantification of atrial fibrillation in patients with dual-chamber pacemakers (2006) (0)
Abstract 12404: Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function over Time: Insights From the ARISTOTLE Trial (2015) (0)
PCV21 THE RELATIVE EFFECTIVENESS PROFILE OF DRONEDARONE USING THE NUMBER NEEDED TO TREAT (NNT) APPROACH (2010) (0)
Issue Information (2017) (0)
Abstract 17617: History of Bleeding and Outcomes with Apixaban versus Warfarin in Patients with Atrial Fibrillation in the ARISTOTLE Trial (2014) (0)
Chapter 55 Ventricular tachyarrhythmias and implantable cardioverter/defibrillator (2010) (0)
74Subclinical atrial fibrillation before and after acute medical illness or noncardiac surgery: insights from ASSERT (2020) (0)
Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants? (2012) (0)
Reversible exercise-induced advanced atrioventricular block due to cardiac sarcoidosis. (2007) (0)
Reply to the Editor: (2005) (0)
Ventricular tachyarrhythmias and implantable cardioverter–defibrillator (2018) (0)
Abstract 3501: Azimilide Reduces Arrhythmic-Related ER visits and Hospitalizations in Patients with an ICD: Results from the SHIELD trial (2006) (0)
REPORTS ON THERAPY Effects of Amiodarone Versus Quinidine and Verapamil in Patients With Chronic Atria) Fibrillation: Results of a Comparative Study and A 2-Year Follow-Up (2016) (0)
[Predictive value of programmed electrostimulation in patients with spontaneous idiopathic ventricular tachycardia]. (1990) (0)
Systolic potentials during ventricular tachycardia are indicative of critical sites within the reentry circuit in patients with coronary artery disease (1998) (0)
Risk of ischemic stroke or systemic embolism in aspirin-treated patients according to clinical presentation of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE or AVERROES (2014) (0)
Atrial pacing as part of hybrid therapy of atrial tachyarrhythmias: Results from a 5 year prospective observational study (2005) (0)
[Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study]. (1992) (0)
Ventricular rate stabilization for treatment of recurrent VT (2017) (0)
Novel oral antithrombotic and antiarrhythmic approaches for atrial fibrillation - Second edition (2011) (0)
The efficacy and safety of apixaban versus warfarin are preserved in patients with atrial fibrillation and extreme body weight: Insights from the ARISTOTLE Study (2018) (0)
P2243The effect of age on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial (2018) (0)
Management von intrazerebralen Blutungen unter oraler Antikoagulation (2019) (0)
Riskstratificationforsuddencardiacdeath:current status and challenges for the future † (2014) (0)
Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis (2022) (0)
69 – T Wave Alternans* (2013) (0)
[Validation of a discontinuously recording, digital long-term ECG system (Siemens-Sirecust 802/850) using a single beat analysis]. (1989) (0)
Patients Central nervous system Tremor Ataxia Dizziness Blurred speech Visual disturbances Thought disorder Fatigue Paresthesias Nightmares Insomnia Confusion Headaches Tinnitus Hallucinations Gastrointestinal Nausea and vomiting Hepatitis Cardiovascular Aggravation of arrhythmia Increase in CHF Oth (2005) (0)
Issue Information (2018) (0)
Detection of atrial fibrillation in patients with dual chamber pacemakers: Holter recordings versus stored electrograms (2005) (0)
P5737Clinical performance of quadripolar left ventricular leads compared to biventricular leads (2018) (0)
QT Dispersion—Any New Thoughts? (1999) (0)
[Clinical pharmacology and electrophysiological properties of dronedarone]. (2010) (0)
Atrial Fibrillation: Is Rate Stabilization a Valid Clinical Strategy? (2001) (0)
[Electrophysiologic diagnosis of tachycardiac ventricular arrhythmias]. (1986) (0)
AMIODARONE AND TORSADE DE POINTES. AUTHORS' REPLY (1995) (0)
LONG-TERM TREATMENT WITH APIXABAN OF PARTICIPANTS FOLLOWING CONCLUSION OF AVERROES (2019) (0)
Electrical storm after ICD implantation (1999) (0)
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial (2020) (0)
Clinical Trials on Atrial Fibrillation/Future Perspectives (2011) (0)
P1034Impact of ablation status on the efficacy and safety of dronedarone in patients with atrial fibrillation/flutter: a post-hoc analysis of the ATHENA trial (2019) (0)
Introduction: Tuning Cardiac Activation for a Better Pulse (2002) (0)
Aalborg Universitet Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation (2019) (0)
901 Does cardiac resynchronization therapy improve outcomes in patients with chronic atrial tachyarrhythmias? Results from the resynchronization for ambulatory heart failure trial (RAFT) (2011) (0)
Clinical outcomes of subcutaneous vs. transvenous implantable defibrillator therapy in a polymorbid patient cohort (2022) (0)
Reply to the Editor—Electrogram Confirmation of Atrial High-Rate Episodes (2012) (0)
Short-term variability of ventricular arrhythmia and rapid assessment of drug efficacy. (1991) (0)
[Pharmacological therapy for ventricular arrhythmias: evidence for current treatment strategies and perspectives for the future]. (2006) (0)
[Anti-arrhythmia drugs in geriatric patients]. (1991) (0)
P4747Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation (2019) (0)
[Drug therapy of ventricular arrhythmias - a contemporary perspective]. (2002) (0)
Highlights of Heart Rhythm 2006, the Annual Scientific Sessions of the Heart Rhythm Society: May 17 to 20, 2006, in Boston, Massachusetts (2006) (0)
Abstract 17712: Similar Survival but Higher Incidence of Hardware-Related Complications in Female Implantable Cardioverter Defibrillator Recipients (2010) (0)
P2642Effect of rivaroxaban on coagulation and inflammation biomarkers: results from an X-VeRT substudy (2017) (0)
Abstract 20251: Intracoronary Administration of Bone Marrow-Derived Mononuclear Cells and Arrhythmic Events in Patients with Chronic Heart Failure (2010) (0)
Microvolt T‐wave alternans testing should be used to guide arrhythmic therapy in heart failure patients (2012) (0)
Electrocardiographic Hallmark of Arrhythmogenic Right Ventricular Cardiomyopathy (2006) (0)
Incidence and risk of short episodes of atrial fibrillation detected with 14 days of continuous electrocardiographic monitoring (2020) (0)
[Anti-arrhythmia agents following a myocardial infarct: the results of the CAST study. Cardiac Arrhythmia Suppression Trial]. (1991) (0)
Differences in baseline electrophysiologic properties and electrical remodeling among pacemaker patients who develop atrial tachyarrhythmias : results of the ASSERT mechanisms of atrial fibrillation St (2011) (0)
HIGH-VOLTAGE ICD LEAD IMPEDANCES ARE NOT INCREASED BY ROUTINE DEFIBRILLATION TESTING: Results FROM THE SIMPLE STUDY (2015) (0)
Oral Antithrombin Agents: Will They Replace Warfarin? (2006) (0)
Intracoronary thrombolysis following failed intravenous thrombolysis with prourokinase in patients with acute myocardial infarction (1990) (0)
Can microvolt T-wave alternans predict mortality in patients with ischemic cardiomyopathy? (2006) (0)
A Reappraisal in 2005 (0)
Novel antiarrhythmic approaches to treatment of atrial fibrillation (2011) (0)
Prevention of stroke in patients with atrial ﬁbrillation: current strategies and future directions (2008) (0)
ESC 2012 Clinical Trial and Registry Updates I Headline findings and implications for patients and clinicians (2013) (0)
Abstract 13392: Efficacy and Safety of Dronedarone vs Placebo Across Age and Sex Subgroups: A Post Hoc Analysis of the Athena Study Among Patients With Nonpermanent Atrial Fibrillation/flutter (2020) (0)
P2298High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI (2018) (0)
The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation (2015) (0)
[Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation]. (2015) (0)
[Prognostic significance of the QT-interval following myocardial infarction]. (1984) (0)
[Toxic myocardial damage in meningococcal infection]. (1986) (0)
Issue Information (2017) (0)
174 Circulation July 9 , 2013 Sudden Cardiac Death in Heart Failure (2013) (0)
Issue Information (2018) (0)
ACTIVE W Substudy Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in (2011) (0)
Is there a role for verapamil beyond rate control in paroxysmal atrial fibrillation? (2021) (0)
[Microvolt level T wave alternans: a new marker for noninvasive risk stratification]. (2000) (0)
P4784Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial (2019) (0)
Assessment of autonomic tonus and reflexes in patients after myocardial infarction (1994) (0)
P2777Accumulating evidence for deleterious effects of digoxin in heart failure and atrial fibrillation: an updated meta-analysis (2018) (0)
Abstract 4095: Maintenance of Sinus Rhythm Is Not Associated with Improved Survival in Patients with Atrial Fibrillation and Heart Failure (2008) (0)
[Proarrhythmic effects of anti-arrhythmia agents]. (1990) (0)
'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply. (2013) (0)
Off-Label Use of Direct Oral Anticoagulants Should Be Considered in Intracerebral Hemorrhage Patients With Prosthetic Valves (2017) (0)
Questionable levels of evidence in new atrial fibrillation guidelines? Reply. (2013) (0)
P1668Cephalic versus subclavian lead implantation in cardiac implantable electronic devices: a systematic review and comprehensive meta-analysis (2017) (0)
Detection of traumatic myocardial injury by means of simultaneous Tl-201/Tc-99m pyrophosphate tomography--report of three cases. (1990) (0)
P34 The effect of sex on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial (2018) (0)
Chapter 30 – Evaluation and Management of Arrhythmias in Dilated Cardiomyopathy and Congestive Heart Failure (2005) (0)
How to maximize QRS narrowing (2019) (0)
Dronedarone as early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET4 criteria (2022) (0)
Avoiding ICD lead revision in a patient with chronically low R-wave amplitudes (2020) (0)
No , Off-Label Use of DOACs Should Not Be Considered in ICH Patients With Prosthetic Valves (2017) (0)
[Management of oral anticoagulation related intracerebral hemorrhage]. (2019) (0)
Dispersion of Ventricular Repolarization - Myocardial and Electrocardiographic Markers (1997) (0)
874-3 Assessment of microvolt T wave alternans on and off beta-blocker therapy (2004) (0)
Abstract 20134: Similar Heparin Dosing in Uninterrupted Anticoagulation Treatment With Dabigatran Etexilate versus Warfarin in Catheter Ablation of Atrial Fibrillation: The Re-Circuit Study (2017) (0)
Lack of stability of late potentials during the first year after myocardial infarction in the thrombolytic era (1996) (0)
P3-7: Characterization of a novel target for atrial selective drug therapy: KV1.5 based transient outward current (2006) (0)
Abstract 19504: Factors Predicting Sinus Rhythm in Patients Cardioverted in the X-VERT Study (2014) (0)
Hazards of Atrial Overdrive Pacing Delivered to Prevent Atrial Fibrillation (2012) (0)
SAFETY OUTCOMES WITH ANESTHESIOLOGIST DIRECTED SEDATION COMPARED TO NON-ANESTHESIOLOGIST FOR DEFIBRILLATION THRESHOLD TESTING (2017) (0)
[Implantable sensors for outpatient assessment of ventricular filling pressure in advanced heart failure : Which telemonitoring design is optimal?] (2016) (0)
Off-Label Use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients With Prosthetic Valves. (2017) (0)
Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation (2015) (0)
Visits and Hospitalizations in Patients With an Implantable Cardioverter-Defibrillator in a Placebo-Controlled Clinical Trial (2016) (0)
Abstract 1880: Molecular Basis of Inward-Rectifier Potassium Current Upregulation in Human Atrial Fibrillation: Contrasting Mechanisms for IK1 versus Constitutive IKACh (2008) (0)
Photofeature: European cardiovascular researchers on holiday and outside of work (2010) (0)
Abstract 18003: Patients With Good Adherence to Study Medication Have Better Outcomes: Insights From the ARISTOTLE Trial (2017) (0)
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial (2022) (0)
Risk factor assessment: defining populations and individuals at risk. (2008) (0)
Clinical Value of d,l-sotalol: Overview of Recent Trials (2000) (0)
Atrial fibrillation Digoxin-associated mortality : a systematic review and meta-analysis of the literature (2015) (0)
Abstract 2556: Differential Predictive Value of Biomarkers for Atrial Fibrillation-related Mortality and Vascular Events: A Prospective Study (2009) (0)
Issue Information (2017) (0)
USE OF INTERACTING DRUGS DID NOT MODIFY TREATMENT EFFECTS OF APIXABAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL (2017) (0)
Flash Presentations (2022) (0)
[Ventricular arrhythmia in silent myocardial ischemia--diagnosis and clinical relevance]. (1989) (0)
P1901De novo atrial fibrillation after DDD pacemaker implantation (2018) (0)
Issue Information (2018) (0)
Repolarization Alternans Facilitated by Structural Abnormalities of the Heart: Another Piece of the Puzzle (2001) (0)
Abstract 5695: Arrhythmogenic Cardiac Death in Implantable Cardioverter Defibrillator Recipients: A Long-term Study of 783 Consecutive Patients (2008) (0)
1091-223 The implantable defibrillator and the long QT syndrome: An overview of current use and outcome (2004) (0)
β-Blocker-Therapie bei akutem Myokardinfarkt (1997) (0)
QT-Dispersion: Role in Clinical Decision Making (2000) (0)
Novel oral antithrombotic and antiarrhythmic approaches for atrial fibrillation (2011) (0)
Abstract 1507: Disruption of KCNH2 Trafficking May Contribute to Severe Clinical Phenotype of Trafficking Deficient Long-QT Type-1 Mutation KCNQ1-T587M (2008) (0)
Complete tear-off of a Riata dual coil lead tip. (2016) (0)
[Pathophysiologic relevance and prognostic value of QT dispersion]. (1997) (0)
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". (2014) (0)
Abstract 17221: Incidence of Pacemaker-Detected Atrial Tachyarrhythmias in Elderly Patients with Hypertension and a History of Stroke or Transient Ischemic Attack (2012) (0)
Randomized Trial Support for Primary and Secondary Prevention of ICD Therapy (2013) (0)
4365Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients: a retrospective, observational study on 71,000 patients with non-valvular atrial fibrillation (2018) (0)
Management Options in Atrial Fibrillation – The Role of Vernakalant (2012) (0)
[Pharmacological therapy of atrial fibrillation and atrial flutter]. (2002) (0)
[Electrophysiological studies on the specific effects of new anti-arrhythmia agents]. (1983) (0)
Highlights of Heart Rhythm 2005, the Annual Scientific Sessions of the Heart Rhythm Society, May 4-7, 2005, New Orleans, Louisiana. (2005) (0)
Response to Letter Regarding Article, “Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)” (2013) (0)
T Wave Alternans in Ischaemic Heart Disease (2007) (0)
Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. (2019) (0)
Electrophysiologic effects of enoximone in patients with congestive heart failure. (1989) (0)
T Wave Alternans and Left Ventricular Ejection Fraction, but Not QT Variability Index, Predict Appropriate ICD discharge (1999) (0)
Abstract 2756: Time Dependent Efficacy of Budiodarone, an Analog of Amiodarone, in Patients With Paroxysmal AF and Implantable Pacemaker Capable of Monitoring Rhythm (2009) (0)
[Anticoagulation for Stroke Prevention in Atrial Fibrillation]. (2020) (0)
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. (2023) (0)
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE‐DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials) (2021) (0)
Abstracts: Ventricular Fibrillation Induction at implant: hot issues (2009) (0)
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial (2020) (0)
[Paroxysmal supraventricular tachycardia. Diagnostic methods]. (1998) (0)
An Irregular, Narrow QRS Complex Tachycardia With Ventriculoatrial Block: (1999) (0)
Clinical pharmacology and electrophysiologicalproperties of dronedarone (2010) (0)
Digoxina y mortalidad en pacientes con fibrilación auricular (2018) (0)
DINAMIT: Does ICD Implantation Improve Life Expectancy in Survivors of Acute Myocardial Infarction? (2000) (0)
Repeated assessment of microvolt level T-wave alternans in patients with acute myocardial infarction and reduced LVEF: Results from a long-term follow-up study (2005) (0)
Comparison of ice Daily dministered En Potentially Lethal Vent ythmias (1989) (0)
Incidence and importance of silent myocardial ischaemia — treatment with gallopamil (1989) (0)
Have MADIT and Recent Post Myocardial Infarction Amiodarone Studies Changed the Classical Indications for ICD Implantation (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stefan Hans Hohnloser?

Stefan Hans Hohnloser is affiliated with the following schools:

Stefan Hans Hohnloser's Academic­Influence.com Rankings

Why Is Stefan Hans Hohnloser Influential?

Stefan Hans Hohnloser's Published Works

Published Works

What Schools Are Affiliated With Stefan Hans Hohnloser?

Stefan Hans Hohnloser's AcademicInfluence.com Rankings